Rare disease drug developer BioMarin Pharmaceutical is buying its way to revenue growth with a $4.8 billion deal for Amicus Therapeutics, a company whose two commercialized products each offer ...

A coalition of major pharmacy organizations urged Congressional leaders to enact long-stalled PBM reforms to curb ...

Recent changes to ACIP leadership and vaccine guidance have raised concerns that longstanding immunization protections are ...

The Senate’s rejection of two ACA-focused healthcare bills widened partisan divides and sparked warnings from advocacy groups ...

Texas Attorney General Ken Paxton sued Epic, alleging the company monopolizes the EHR market and restricts access to medical ...

An Eli Lilly drug candidate designed to hit three metabolic targets led patients to lose an average of 28.7% of their body weight in a late-stage clinical trial, setting a new high mark in the ...

Scholar Rock contends its experimental drug for spinal muscular atrophy can achieve what none of the currently available therapies can do to treat this rare disease. After positive data from a pivotal ...

Mark Cuban warned that many employers are collecting drug rebate money funded by their sick employees — a practice that can ...

Senate Finance Committee Chairman Mike Crapo (R-Idaho) and Ranking Member Ron Wyden (D-Oregon) introduced a bill Thursday that aims to bring more transparency into the practices of pharmacy benefit ...

Abbott’s $23 billion acquisition of Exact Sciences positions the company to become a major player in cancer diagnostics. Experts think the deal makes strategic sense, as it offers higher margins and a ...

Empathy Health Technologies announced Wednesday that it raised $7.6 million to support its Sober Sidekick app, which helps prevent relapse by connecting those struggling with substance use disorder ...